Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component
- PMID: 29920539
- PMCID: PMC6007912
- DOI: 10.1371/journal.pone.0199164
Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component
Abstract
Background: In pulmonary hypertension (PH), both wedge pressure elevation (PAWP) and a precapillary component may affect right ventricular (RV) afterload. These changes may contribute to RV failure and prognosis. We aimed at describing the different haemodynamic phenotypes of patients with PH due to left heart disease (LHD) and at characterizing the impact of pulmonary haemodynamics on RV function and outcome PH-LHD.
Methods: Patients with PH-LHD were compared with treatment-naïve idiopathic/heritable pulmonary arterial hypertension (PAH, n = 35). PH-LHD patients were subdivided in Isolated post-capillary PH (IpcPH: diastolic pressure gradient, DPG<7 mmHg and pulmonary vascular resistance, PVR≤3 WU, n = 37), Combined post- and pre-capillary PH (CpcPH: DPG≥7 mmHg and PVR>3 WU, n = 27), and "intermediate" PH-LHD (either DPG <7 mmHg or PVR ≤3 WU, n = 29).
Results: Despite similar PAWP and cardiac index, haemodynamic severity and prevalence of RV dysfunction increased from IpcPH, to "intermediate" and CpcPH. PVR and DPG (but not compliance, Ca) were linearly correlated with RV dysfunction. CpcPH had worse prognosis (p<0.05) than IpcPH and PAH, but similar to "intermediate" patients. Only NTproBNP and Ca independently predicted survival in PH-LHD.
Conclusions: In PH-LHD, haemodynamic characterization according to DPG and PVR provides important information on disease severity, predisposition to RV failure and prognosis. Patients presenting the CpcPH phenotype appear to have haemodynamic profile closer to PAH but with worse prognosis. In PH-LHD, Ca and NTproBNP were independent predictors of survival.
Conflict of interest statement
JLV is the holder of the Actelion Research Chair on Pulmonary Hypertension in his department. SC is the recipient of a ERS PAH Short-Term Research Training Fellowship (STRTF 2014-5264) supported by an unrestricted grant by GSK, and of the international grant “Cesare Bartorelli” for the year 2014 funded by the Italian Society of Hypertension. This does not alter our adherence to PLOS ONE policies on sharing data and materials. None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of the present manuscript or other conflicts of interest to disclose.
Figures



Similar articles
-
Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component.J Heart Lung Transplant. 2017 Jul;36(7):754-762. doi: 10.1016/j.healun.2016.12.011. Epub 2016 Dec 23. J Heart Lung Transplant. 2017. PMID: 28131663
-
Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.Eur J Heart Fail. 2018 Feb;20(2):248-255. doi: 10.1002/ejhf.860. Epub 2017 May 2. Eur J Heart Fail. 2018. PMID: 28464427
-
Significance of Pulmonary Vascular Resistance and Diastolic Pressure Gradient on the New Definition of Combined Post-Capillary Pulmonary Hypertension.Int Heart J. 2020;61(2):301-307. doi: 10.1536/ihj.19-476. Int Heart J. 2020. PMID: 32224602
-
The Diagnostic Challenge of Group 2 Pulmonary Hypertension.Prog Cardiovasc Dis. 2016 Jul-Aug;59(1):22-9. doi: 10.1016/j.pcad.2016.05.003. Epub 2016 May 16. Prog Cardiovasc Dis. 2016. PMID: 27195751 Review.
-
Pulmonary hypertension due to left heart diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. doi: 10.1016/j.jacc.2013.10.033. J Am Coll Cardiol. 2013. PMID: 24355634 Review.
Cited by
-
Impact of severe secondary tricuspid regurgitation on rest and exercise hemodynamics of patients with heart failure and a preserved left ventricular ejection fraction.Front Cardiovasc Med. 2023 Mar 1;10:1061118. doi: 10.3389/fcvm.2023.1061118. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36937944 Free PMC article.
-
Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction.Am J Physiol Heart Circ Physiol. 2024 Jun 1;326(6):H1498-H1514. doi: 10.1152/ajpheart.00068.2024. Epub 2024 Apr 19. Am J Physiol Heart Circ Physiol. 2024. PMID: 38639739 Free PMC article. Review.
-
Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension.J Vet Intern Med. 2023 May-Jun;37(3):856-865. doi: 10.1111/jvim.16686. Epub 2023 Mar 30. J Vet Intern Med. 2023. PMID: 36994902 Free PMC article.
-
Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?Pulm Circ. 2021 May 29;11(2):20458940211018074. doi: 10.1177/20458940211018074. eCollection 2021 Apr-Jun. Pulm Circ. 2021. PMID: 34104424 Free PMC article. No abstract available.
-
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.Eur J Heart Fail. 2024 Apr;26(4):707-729. doi: 10.1002/ejhf.3236. Epub 2024 Apr 19. Eur J Heart Fail. 2024. PMID: 38639017 Free PMC article.
References
-
- Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46:903–75 doi: 10.1183/13993003.01032-2015 - DOI - PubMed
-
- Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013;62:D100–8 doi: 10.1016/j.jacc.2013.10.033 - DOI - PubMed
-
- Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013;41:217–23 doi: 10.1183/09031936.00074312 - DOI - PubMed
-
- Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013;143:758–66. doi: 10.1378/chest.12-1653 - DOI - PubMed
-
- Gerges M, Gerges C, Lang IM. How to define pulmonary hypertension due to left heart disease. Eur Respir J 2016; 48(2):553–5 doi: 10.1183/13993003.00432-2016 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials